Navigation Links
Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
Date:10/3/2007

ocyte Macrophage Colony Stimulating Factor) and IL-2 (Interleukin-2). For the latter two, Zenotech is the first to receive approvals in India, and has a pipeline of further seven Biopharmaceutical products in different stages, all developed in-house. It has state-of-the-art manufacturing facilities in Hyderabad, India, while its R&D facilities are in Hyderabad and New Jersey, USA.

Speaking of the expanded relationship, Mr. Dipak Chattaraj, President, Business Development, Ranbaxy, said, "Over the past two years, we have shared a wonderful working relationship with great Chemistry between our two organizations. The decision to expand our engagement is a statement of our unified goal to make India a strong contender in the international Biopharmaceuticals market."

Presently, the Global Biopharmaceuticals market is valued at app. USD 65 Bn at innovator prices and Zenotech's pipeline addresses a third of this market. The Global Oncology market is worth over USD 35 Bn and is considered among the fastest growing therapeutic segments globally. Speciality Injectables are a high value addition segment, compared with orals and Ranbaxy plans to file seven US ANDAs from Zenotech facilities in the coming few months.

Zenotech Laboratories Limited is a Specialty Generic Injectables company with strong expertise in the area of Bio-technology. Zenotech's predominantly high value injectables product portfolios serve niche therapy areas like Oncology and Anesthesiology. Zenotech has Research and Development facilities in India and in the U.S. Its oncology and biologics manufacturing facilities are located near Hyderabad, India.

Ranbaxy Laboratories Limited, India's largest Pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approva
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Fiserve Acquires RegEd, Consolidates N.C.-Based Operations in Wisconsin
2. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
3. Wisconsin early-stage companies must position themselves to get capital
4. New UW position focusing on Internet security
5. Midwest holds strong position in worldwide diagnostics business
6. Doyle praises Frists new stem cell research position
7. GE promotes Milwaukee-area CEO to London position
8. Is IT leadership a position or an attitude?
9. nPoint announces new nanopositioning scanning control mode
10. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
11. National stem-cell panel, including UW profs, urges close watch on research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... , , , The proven activated dendrimer for transfection , ... Features and benefits , , ... Suitable for a broad range of cell lines , Transfection in ... Quantity vs. Transfection Efficiency ") , High transient and stable transfection ...
... , , , For transfection of a wide variety of cells, , ... Features and benefits , , ... transfection-complex removal needed for most cell lines , Transfection in the ... lines , High transfection efficiencies and minimal cytotoxicity, ...
... , , , , ... and Rosemarie Grantyn , Developmental Physiology, Johannes Mller ... , , Efficient ... importance for extending our knowledge of the molecular basis of neuronal ...
Cached Biology Technology:SuperFect Transfection Reagent 2SuperFect Transfection Reagent 3Effectene Transfection Reagent 2Effectene Transfection Reagent 3Effectene Transfection Reagent 4Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 2Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 3Effectene Transfection Reagent provides efficient gene delivery , to primary neuronal cell cultures 4
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... biologists at the University of Pennsylvania say that species ... rate than in the past. In the study, ... researchers developed a novel computational approach to infer the ... present-day species. Using nine patterns of diversification as ...
... State University researchers have received a $1.5 million ... better account of their ecological footprint., Seven researchers ... Natural Resources, Biosystems Engineering, and USDA Agricultural Research ... nitrogentwo elements central to farming and out of ...
... more than $4.5 million, from agencies of the National ... treatment strategies for muscular dystrophy. The grants were ... and Skin Diseases (NIAMS), National Institute of Neurological Disorders ... of Child Health and Human Development (NICHD) for year ...
Cached Biology News:Penn biologists say species accumulate on Earth at slower rates than in the past 2WSU researchers taking sustainability of organic farming to new level 2NIH awards Muscular Dystrophy Cooperative Research Center grants 2
... shortages in your laboratory or fellow researchers want ... problems and delays. • ... Bring us your idea and let us build ... under ISO 9001 quality assurance in design, development, ...
...
... virus is a type I eukaryotic topoisomerase ... turns (also called right- and left-handed supercoils) ... the reaction is a covalently closed, circular ... turns. DNA Topoisomerase I does not absolutely ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Biology Products: